NILOTINIB 300 MG TWICE DAILY IS EFFECTIVE AND WELL TOLERATED AS FIRST LINE TREATMENT OF PH-POSITIVE CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: UPDATED RESULTS OF THE ICORG 0802 PHASE 2 STUDY

Autoria(s): O'Dwyer, E.; Swords, R.; Giles, F.; LeCoutre, P.; McMullin, Mary Frances; Langabeer, S.; Padmanabhan, S.; Kent, E.; Parker, M.; Moulton, B.; Egan, K.; Conneally, E.
Data(s)

01/06/2010
Identificador

http://pure.qub.ac.uk/portal/en/publications/nilotinib-300-mg-twice-daily-is-effective-and-well-tolerated-as-first-line-treatment-of-phpositive-chronic-myeloid-leukemia-in-chronic-phase-updated-results-of-the-icorg-0802-phase-2-study(14a65252-7ee0-49cd-8286-5708232d2b39).html
Idioma(s)

eng
Direitos

info:eu-repo/semantics/restrictedAccess
Fonte

O'Dwyer , E , Swords , R , Giles , F , LeCoutre , P , McMullin , M F , Langabeer , S , Padmanabhan , S , Kent , E , Parker , M , Moulton , B , Egan , K & Conneally , E 2010 , ' NILOTINIB 300 MG TWICE DAILY IS EFFECTIVE AND WELL TOLERATED AS FIRST LINE TREATMENT OF PH-POSITIVE CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: UPDATED RESULTS OF THE ICORG 0802 PHASE 2 STUDY ' HAEMATOLOGICA , vol 95 , pp. 340-340 .
Tipo

article
Acesso ao item digital